Nathalie Arians, Meinhard Kieser, Laura Benner, Nathalie Rochet, Lars Schröder, Sonja Katayama, Klaus Herfarth, Kai Schubert, Andreas Schneeweiss, Christof Sohn, Katja Lindel, Jürgen Debus
- Background: To assess late toxicity, quality of life and oncological outcome after consolidative whole abdominal radiotherapy (WART) following cytoreductive surgery and carboplatin/paclitaxel chemotherapy in high risk patients with advanced ovarian cancer FIGO stage III using IMRT (Intensity modulated radiation therapy).
Methods: The OVAR-IMRT-02 study is a multi-center single-arm phase-II-trial. Twenty patients with optimally debulked ovarian cancer stage FIGO III with complete remission after chemotherapy were treated with intensity modulated WART. A total dose of 30 Gy in 20 fractions was applied to the entire peritoneal cavity. Primary endpoint was treatment tolerability; secondary objectives were acute and chronic toxicities, quality of life, rates of therapy disruption/abortion, progression-free survival (PFS) and overall survival (OS).
Results: All patients completed treatment and 10/20 patients (50%) reached the final study follow-up of 36 months. Late side effects consisted of °1-°2 lower limb edema (44.5%), with one patient (5.6%) showing °3 edema. Three patients (16.7%) showed elevated gamma-Glutamyltransferase. There were no severe late side effects regarding
renal or hepatic function or any gastrointestinal toxicity greater than °2. During WART, mean global health status
decreased by 18.1 points (95%-CI: 7.1–29.0), but completely normalized after 6 months. The same trend was observed for the function scale scores. Kaplan-Meier-estimated 1-, 2- and 3-year PFS was 74, 51 and 40%, respectively. 1-, 2- and 3-year OS was 89, 83 and 83%, respectively.
Conclusions: Intensity modulated WART after aggressive surgery and carboplatin/paclitaxel chemotherapy is associated with an acceptable risk of acute and late toxicity and minor impact on long-term quality of life. Together
with the promising results for PFS and OS, intensity modulated WART could offer a new therapeutic option for consolidation treatment of patients with advanced ovarian cancer.
Trial registration: The study is registered with ClinicalTrials.gov (NCT01180504). Registered 12 August 2010 – retrospectively registered.
MetadatenAuthor: | Nathalie Arians, Meinhard KieserORCiDGND, Laura Benner, Nathalie Rochet, Lars Schröder, Sonja Katayama, Klaus Herfarth, Kai Schubert, Andreas SchneeweissORCiDGND, Christof Sohn, Katja Lindel, Jürgen DebusORCiDGND |
---|
URN: | urn:nbn:de:hebis:30:3-531221 |
---|
DOI: | https://doi.org/10.1186/s13014-019-1381-2 |
---|
ISSN: | 1748-717X |
---|
Pubmed Id: | https://pubmed.ncbi.nlm.nih.gov/31639066 |
---|
Parent Title (English): | Radiation Oncology |
---|
Document Type: | Article |
---|
Language: | English |
---|
Year of Completion: | 2020 |
---|
Year of first Publication: | 2020 |
---|
Publishing Institution: | Universitätsbibliothek Johann Christian Senckenberg |
---|
Release Date: | 2020/04/09 |
---|
Tag: | consolidation treatment; oncological outcome; ovarian cancer; quality of life; toxicity; whole abdominal radiotherapy |
---|
Volume: | 14 |
---|
Issue: | 179 |
---|
Page Number: | 10 |
---|
First Page: | 1 |
---|
Last Page: | 10 |
---|
HeBIS-PPN: | 466022158 |
---|
Institutes: | Medizin / Medizin |
---|
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
---|
Sammlungen: | Universitätspublikationen |
---|
Licence (German): | Creative Commons - Namensnennung 4.0 |
---|